338840 — Y Biologics Income Statement
0.000.00%
Last trade - 00:00- KR₩280bn
- KR₩255bn
- KR₩3bn
Annual income statement for Y Biologics, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Annual Audited Accounts | Annual Audited Accounts | ARS | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | — | — | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 4,847 | 4,151 | 3,479 | 5,763 | 2,913 |
| Cost of Revenue | |||||
| Gross Profit | 2,388 | 1,336 | 2,389 | 4,373 | 2,381 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 22,212 | 22,899 | 24,858 | 12,878 | 12,744 |
| Operating Profit | -17,365 | -18,748 | -21,379 | -7,115 | -9,831 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -17,071 | -18,804 | -20,871 | -6,442 | -42,025 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -17,071 | -18,804 | -20,871 | -6,442 | -42,025 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -17,071 | -18,804 | -20,871 | -6,442 | -42,025 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -17,071 | -18,804 | -20,871 | -6,442 | -42,025 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1,232 | -1,350 | -796 | -526 | -2,782 |
| Dividends per Share |